Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting
Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024.
- Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024.
- The breadth of new data in different tumor types underscores Bayer’s ambition to deliver innovative and effective oncological therapies in areas with the highest unmet medical needs.
- Prostate cancer is a key focus for Bayer Oncology, with data to be presented on NUBEQA® (darolutamide) and XOFIGO® (radium Ra 223 dichloride) across multiple stages of the disease.
- An overview of the ongoing investigational Phase III ARASTEP trial in hormone sensitive prostate cancer patients with high-risk biochemical recurrence will also be presented.